Pharma & Biotech Mergers & Acquisitions News
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Generics
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
Generics
Viatris has announced that the antitrust division of the US Department of Justice (DOJ) has concluded its investigation into Mylan and its former president, Rajiv Malik. 3 July 2024
Generics
An activist investor has renewed its effort to prevent Taro Pharmaceutical from accepting a buyout bid from Sun Pharmaceutical. 24 April 2024
Generics
Generic drugmaker Apotex has reached an agreement to acquire fellow Canada-based Searchlight Pharma. 5 April 2024
Generics
KELIX bio, an emerging markets biopharmaceuticals platform, has been sold to Mubadala Investment Company, an Abu Dhabi investor with over $276 billion in assets under management. 25 March 2024
Generics
Generic drugmaker Aspire Pharma today announced the successful completion of its acquisition of fellow UK-based Cenoté Pharma, in continuation of its strong organic growth. 11 March 2024
Generics
In a bid to focus on growth and innovation, Israeli generics drugmaker Teva Pharmaceutical is to hive off its active pharmaceutical ingredient (API) business. 1 February 2024
Generics
Sun Pharmaceutical Industries of India announced its intention to acquire all outstanding shares of US generics drugmaker Taro Pharmaceutical Industries at a price of $43 per share in cash, the companies announced. 19 January 2024
Generics
Taiwan’s Bora Pharmaceuticals is to acquire Upsher-Smith Laboratories, a US generics manufacturer. 17 January 2024
Generics
South Africa's largest drugmaker Aspen Pharmacare has announced an agreement with newly-independent generics drugmaker Sandoz, related to its Chinese business. 7 December 2023
Generics
Portuguese contract development and manufacturing organization (CDMO) Hovione has acquired the start-up ExtremoChem for an undisclosed amount. 20 November 2023
Generics
The Indian pharma and healthcare sector has witnessed a 298% jump in deals during the third quarter of 2023 compared to the same period last year. 8 November 2023
Generics
A confluence of factors is creating a conducive environment for mergers and acquisitions (M&As) to pick up pace in India. 23 October 2023
Generics
USA-based drugmaker Viatris has announced a series of divestitures as part of a strategy to narrow the company’s focus. 3 October 2023
Generics
Indian drugmaker Glenmark Pharmaceuticals has entered into a definitive agreement with Nirma Limited to divest a 75% stake in its subsidiary, Glenmark Life Sciences Limited (GLS), which focuses on producing active pharmaceutical ingredients (APIs). 22 September 2023
Generics
Shares of Hyderabad, India-headquartered Suven Pharmaceuticals hit a fresh 52-week high on the bourses after the Indian government gave the green signal to foreign direct investment (FDI) of up to $1.15 billion by drug major Cyprus-based Berhyanda. 19 September 2023
Generics
Several international investors and fund managers have expressed an interest in investing in the Indian pharmaceutical and biotechnology sectors, underlining the need to establish a platform to facilitate the transition of global capital flows into the domestic economy. 14 April 2023
Generics
In what could well be India's biggest pharma deal, China's Fosun Pharma-owned Gland Pharma is on the block. A number of private equity firms have been approached, including Baring Private Equity, Bain Capital, Blackstone, Carlyle, and KKR. 19 December 2022
Generics
Generics major Viatris yesterday said it intends to create an ophthalmology franchise by acquiring two companies, Oyster Point Pharma (Nasdaq: OYST) and Famy Life Sciences. 8 November 2022
Generics
Private equity firm SK Capital Partners has entered into a deal to acquire Apotex Pharmaceutical Holdings, a Canada-based generic drugmaker with products across all major therapeutic areas for patients around the world. 29 September 2022
Generics
Indian drugmaker Sun Pharma, along with its subsidiaries and/or associate companies), have executed a definitive agreement to take a majority stake in a Russian company in order to expand its presence in that market. 23 November 2016
Generics
Japanese drugmaker Mitsui & Co is considering expanding into the Russian pharmaceutical market, through the acquisition of a 10% stake in R-Pharm, one of Russia’s largest pharmaceutical producers. 3 November 2016
Generics
Valeant has issued a statement regarding press comments attributed to anonymous sources report regarding its gastroenterology business unit. 2 November 2016
Generics
Indian company Intas Pharmaceuticals has agreed to buy the assets and operations of Actavis Generics in the UK and Ireland from Israeli drugs giant Teva for £603 million ($762 million). 6 October 2016
Generics
The European Commission has approved under the EU Merger Regulation the acquisition of Anda Distribution of the USA by Teva Pharmaceutical Industries (NYSE: TEVA) of Israel. 15 September 2016
Generics
Mallinckrodt has entered into a definitive agreement under which it will sell its Nuclear Imaging business to IBA Molecular (IBAM). 24 August 2016
Generics
Via its wholly-owned US subsidiary, Indian drugmaker Piramal Enterprises has entered into an agreement to acquire 100% stake in Ash Stevens, a USA-based contract development and manufacturing organization (CDMO). 17 August 2016
Generics
Teva Pharmaceutical Industries has entered into a definitive agreement to purchase Allergan’s Anda subsidiary, the fourth largest distributor of generic pharmaceuticals in the USA. 4 August 2016
Generics
Israeli generics juggernaut Teva Pharmaceutical Industries has ended a long-running saga by completing the deal to buy Actavis Generics from Ireland-incorporated Allergan. 3 August 2016
Generics
Mylan has agreed to divest the rights and assets related to two generic pharmaceutical products to settle US Federal Trade Commission charges that its proposed $7.2 billion acquisition of Swedish drugmaker Meda would be anti-competitive. 29 July 2016
Generics
The US Federal Trade Commission (FTC) has approved Teva Pharmaceutical Industries’ takeover of the generics arm of Ireland-incorporated Allergan – subject to the Israeli company’s divestment of dozens of generic drugs. 28 July 2016
Generics
Israeli generics giant Teva Pharmaceutical Industries has attracted more than 30 billion euros ($33.04) of orders for a four billion euros bond sale in Europe. 22 July 2016
Generics
The European Commission has approved under the EU Merger Regulation the proposed $7.2 billion acquisition of Sweden’s Meda by Netherlands-incorporated drugmaker Mylan, subject to conditions. 21 July 2016
Generics
Teva Pharmaceutical Industries will raise between $20 billion and $25 billion in a multi-currency bond sale to pay for its $40.5 billion acquisition of the generics business of Ireland-incorporated company Allergan. 15 July 2016
Generics
After decades of manufacturing generics, China is eager to catch up with novel drug development for further growth, says The Pharma Letter’s local correspondent Wang Fangqing. 4 July 2016
Generics
Italy-based P&R Group has signed a binding agreement to acquire 100% of the Italian pharmaceutical chemical manufacturer, Infa Group through the P&R subsidiary Olon SpA. 26 May 2016
Generics
Shanghai-based Fosun Pharma has announced an indicative offer to buy Gland Pharma, which is based in Hyderabad, India, competing against the US pharma firm Baxter, the other potential buyer. 23 May 2016
Generics
The assets of Israeli drugmaker Teva Pharmaceutical International in the UK, Ireland and Iceland have attracted interest from bidders including Netherlands-incorporated Mylan and Swiss pharma giant Novartis, Bloomberg reports. 16 May 2016
Generics
Mylan is to acquire the non-sterile, topicals-focused specialty and generics business of Renaissance Acquisition Holdings. 14 May 2016
Generics
Albany Molecular Research has signed a definitive agreement to acquire all outstanding shares of Prime European Therapeuticals, also known as "Euticals," in a transaction valued at around $358 million (315 million euros), consisting of shares of AMRI common stock, cash and a seller note. 5 May 2016
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze